See more : Surgutneftegas Public Joint Stock Company (SGTZY) Income Statement Analysis – Financial Results
Complete financial analysis of Rezolute, Inc. (RZLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rezolute, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Reliability Incorporated (RLBY) Income Statement Analysis – Financial Results
- Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (002864.SZ) Income Statement Analysis – Financial Results
- C’sMEN Co.,Ltd. (3083.T) Income Statement Analysis – Financial Results
- Avoca LLC (AVOA) Income Statement Analysis – Financial Results
- PT Adaro Energy Indonesia Tbk (ADOOY) Income Statement Analysis – Financial Results
Rezolute, Inc. (RZLT)
About Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 36.00K | 382.00K | 256.00K | 303.00K | 18.00K | 48.00K | 1.07M | 12.57M | 8.27M | 5.85M | 2.40M | 4.56M | 4.84K |
| Gross Profit | -36.00K | -382.00K | -256.00K | -303.00K | -18.00K | -48.00K | -1.07M | -12.57M | -8.27M | -5.85M | -2.40M | -4.56M | -4.84K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 55.74M | 43.81M | 32.49M | 14.99M | 14.45M | 19.08M | 17.28M | 12.09M | 9.45M | 4.70M | 34.32K | 3.49K | 0.00 |
| General & Administrative | 196.00K | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M | 5.50M | 6.00M | 5.13M | 6.10M | 42.67M |
| Selling & Marketing | 14.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -42.63M |
| SG&A | 14.64M | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M | 5.50M | 6.00M | 5.13M | 6.10M | 42.67K |
| Other Expenses | 0.00 | 0.00 | -231.00K | -515.00K | 0.00 | 321.00K | 136.13K | 37.14K | 5.33M | 3.51M | 11.30K | 295.00 | 6.62M |
| Operating Expenses | 70.42M | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M | 26.38M | 20.32M | 14.95M | 10.70M | 5.18M | 6.11M | 42.67K |
| Cost & Expenses | 70.42M | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M | 26.38M | 20.32M | 14.95M | 10.70M | 5.18M | 6.11M | 47.51K |
| Interest Income | 0.00 | 4.21M | 80.00K | 63.00K | 188.00K | 61.00K | 1.00K | 0.00 | 965.00 | 4.97K | 12.18K | 106.04K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.81M | 375.00K | 0.00 | 4.96M | 689.19K | 1.60K | 5.04K | 6.73K | 4.23M | 568.86K | 0.00 |
| Depreciation & Amortization | 36.00K | 382.00K | 256.00K | 303.00K | 18.00K | 48.00K | 1.07M | 1.11M | 751.25K | 134.13K | 11.30K | 295.00 | 221.00 |
| EBITDA | -68.42M | -51.41M | -41.83M | -22.88M | -20.32M | -25.44M | -28.11M | -19.16M | -14.18M | -11.22M | -5.49M | -6.16M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -70.42M | -55.99M | -41.84M | -22.89M | -20.52M | -25.94M | -28.73M | -20.32M | -14.95M | -10.70M | -5.18M | -6.11M | -45.73K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.96M | 4.20M | 783.00K | 1.99M | 188.00K | -4.50M | -1.13M | 46.92K | 15.75K | -664.48K | -4.55M | -620.58K | -1.78K |
| Income Before Tax | -68.46M | -51.79M | -41.06M | -20.90M | -20.33M | -30.45M | -29.86M | -20.28M | -14.94M | -11.36M | -9.73M | -6.73M | -47.51K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -137.90K | -2.28M | 375.00K | -297.00 | -29.00K | 2.93M | -11.37K | -19.82K | 662.72K | 336.49K | 157.76K | 3.56K |
| Net Income | -68.46M | -51.79M | -38.78M | -21.28M | -20.33M | -30.42M | -29.86M | -20.28M | -14.94M | -11.36M | -9.73M | -6.73M | -49.29K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.33 | -1.01 | -2.13 | -2.77 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 | -54.21 | -0.64 |
| EPS Diluted | -1.33 | -1.01 | -1.99 | -2.77 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 | -54.21 | -0.64 |
| Weighted Avg Shares Out | 51.47M | 51.19M | 18.20M | 7.67M | 5.75M | 1.78M | 1.11M | 825.93K | 495.46K | 419.00K | 187.69K | 124.09K | 77.35K |
| Weighted Avg Shares Out (Dil) | 51.47M | 51.19M | 19.49M | 7.67M | 5.75M | 1.78M | 1.11M | 825.93K | 495.46K | 419.00K | 187.69K | 124.09K | 77.35K |
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
Tracking to Announce Top line data in Q1 2022
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, today announced that Nevan Charles Elam, CEO and Founder, will present at two...
Rezolute Added to Russell Microcap® Index
REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, has been added to the Russell Microcap® Index at the conclusion of the...
5 Stock Gainers For May 27: VTNR, GOED, RZLT, AMC, RVPH
Here is an overview of 5 of the top stock gainers for May 21 and why the stock prices moved. The post 5 Stock Gainers For May 27: VTNR, GOED, RZLT, AMC, RVPH appeared first on Pulse 2.0.
RZLT Stock Price: Over 85% Increase Explanation
The stock price of Rezolute Inc (NASDAQ: RZLT) increased by over 85% during intraday trading. This is why it happened.
Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the addition of Davelyn Hood, MD, to its leadership team...
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, today announced that management will present at the Oppenheimer Rare and Orphan Disease Summit....
Rezolute to Participate in Upcoming Investor Conferences in March
REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company's CEO and Founder, will be presenting at the following upcoming investor conferences:
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020.
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME
Source: https://incomestatements.info
Category: Stock Reports